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Abstract
Background: A large fraction of anti-malaria medicines (and indeed many other medicines classes) used in
developing countries are inadequately identified. Framing this problem as one of misidentification rather than the
more common framing of criminal misrepresentation leads to new solutions sets not currently being considered.
Method: That reframing led to consideration and analysis of 4 new problems that informed design of a digital
platform technology for delivering a distributed medicine characterization system: 1) problematic interests
associated with a focus on preventing counterfeiting, 2) the complexity of the many ways that medicines can
deviate from expected identities, 3) the challenge of choosing amongst a diversity of attribute characterization
technologies, and 4) the need for a flexible and distributed data aggregation mechanism.
Results: Analysis of those new problems confirmed an initial insight that a previously described digital technology
for tracking malaria tests results in infrastructure limited regions could be adapted for characterizing pill attributes.
Feasibility is illustrated by describing how the platform design can be implemented using open-source software
and commodity computational and communication technology readily available and supportable in developing
countries.
Discussion: A system of this type would allow users to answer several questions. Is this medicine what it is
supposed to be? Can it be used to treat locally encountered malaria? What has been the experience of others who
have used pills having the same identity? Ubiquitous access to global digital telecommunication infrastructure
allows the system to generate data streams from these distributed medicine characterization transactions that can
be used to map global patterns of use of specifically identified medicines. This can provide feedback necessary to
guide efforts to reduce the burden of malaria.
Background
High-income countries have managed to reduce prevalence
of inadequately identified medicines into their health
systems to less than 1%. This achievement is the result of
a strict regulatory framework governing the production
and distribution of pharmaceutical products and harsh
sanctions for offenders [1]. But, increased globalization of
the market for medicine precursors and the medicines
themselves has caused a proliferation of alternative
formulations and is straining supply-side approaches to
medicine use regulation [2,3].
Low- and middle-income countries face serious
infrastructure limitations in the implementation of such
supply-focused approaches to regulating medicines
in use [4,5]. It estimated that as much as 25-50% of
medicine purchased in developing countries deviate
substantially from the pharmacopoeial specifications of
the medicine that was intended to be purchased; a sig-
nificant fraction are outright fakes [1,6-10]. Although
direct characterization of anti-malaria medicines found
in the health systems of several developing countries
[6-8] have confirmed the seriousness of the problem,
there is no mechanism for routinely characterizing the
extent and dynamics of this misidentification problem in
an on-going manner. * Correspondence: p.pennefather@utoronto.ca
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chaotic health care system [5] as well as resulting
deficits in healthcare quality assessment and develop-
ment capacity [4]. Information asymmetries [5] and
endemic corruption [11] often subvert reliable but
expensive supply-side quality assurance strategies devel-
oped for high-income country settings were expertise,
resources, and infrastructure necessary for their imple-
mentation are readily available and costs can be rolled
into the purchase price [9,11]. Although top-down
reforms aimed at more policing and greater regulation
of medicine producers and distributors are undoubtedly
needed [1,6,9-11], this paper considers a complimentary
alternative approach.
Framing the problem as one of misidentification
rather than one of criminal misrepresentation of the
pill suggests efforts should be put into developing a
user-centred pill characterization system. Such a
system would allow results of these material character-
ization transactions to be aggregated in real-time via
digital networking technology, producing pill charac-
terization data streams that can be shared over the
Internet. This is important because exposures to medi-
cines with mistaken identities represent a serious pub-
lic health threat. Failure to realize what medications
are actually being used results in a vicious cycle that is
of particular relevance for understanding determinants
of the global burden of infectious diseases like malaria.
Infectious diseases in low-income settings are com-
mon. Treatment with anti-infective products that do
not perform as expected because they are not what
they are thought to be leads to a greater exposure to
poorly treated disease than necessary thereby promot-
ing development of drug resistance and further
increasing disease burdens [8]. This situation also leads
to a breakdown in trust in health system efforts to
deal with that burden.
Implementation of a user-focused pill characterization
system would improve clarity throughout the health
system regarding the nature and distribution of anti-
m a l a r i a l si nu s e .I no r d e rt oimprove effectiveness of
drug therapy system-wide, it is necessary to communi-
cate information about the nature of drugs being used
to all participants in the system linking end-users to
producers and dispensers. If the medication in question
was deliberately produced to misrepresent its identity,
greater access to information about the nature of the
actual product being misrepresented will make it harder
to get away with that deceit. If product identification
was compromised inadvertently, the causes leading up
to that mistake can be identified and dealt with. The
methodology described here for tracking results of local
medicine characterizations uses locally sustainable tech-
nology and easily supported web-based interpretive
services. Such a system would enable a necessary
feedback loop for guiding both local and system-wide
treatment quality assessment efforts [9,10].
A user-focused pill characterization system must
enable comparison of readily characterized identity
metrics obtained with the product-at-hand to those
associated with known medicine products (reference
standards). Simple chemical analysis kits (based on for
example thin layer chromatography) which enable direct
comparison with reference standards have been used to
provide rudimentary assessments of deviations from
those reference standards. Such systems are currently
being deployed as a means of evaluating the magnitude
of the mistaken medicine problem [8] and as a means of
extending the capacity of medicine regulatory authorities
[ 1 2 ] .B u t ,t h o s es i m p l ea n a l o gt e s tk i t so n l yp r o v i d ea
limited and local assessment of deviations [10]. This
paper describes how a recently described tele-microbiol-
ogy framework for distributed malaria diagnostic tests
based on sharing telemicroscopy images of blood smears
[13] can be adapted to help characterize identifying
attributes of anti-malarial medicines. The design of this
adaptation builds on recently described non-destructive
digital spectroscopy technologies that can measure char-
acteristic chemical signatures of pills even through
packaging [14].
Digital identity metrics, coupled with ubiquitous
digital information and communication infrastructure
[15,16] enables creation of real-time medicine identifica-
tion data streams that can be used to map global
patterns of exposure to specific products sold as anti-
malarials [3,17]. Real-time medicine identification data
streams would begin to address one important aspect of
existing information asymmetries commonly found in
relatively unorganized health care markets. It would
allow local users and distributors to know the answers
to some important questions. Is this medicine-(product)
what it is supposed to be? Can it be used to treat locally
encountered malaria? What has been the experience of
others who have used pills having the same identity?
Answers to those questions would highlight which pro-
curement policies deliver the most effective medicines
possible within given sets of constraints (including
price). Those answers would facilitate adaptation of
medicine-use behaviour and future procurement strate-
gies in ways that enhance end-user safety and generate
more satisfactory medication experiences. At a mini-
mum, distribution patterns for specific anti-malarial
products and their imitators would become more evident.
A combination of local experience and external support
anchored by clarity around what anti-malarial products
were actually used would then enable quality assessment
systems to be developed and dangerous trends to be
recognized early.
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Reframing the problem as medicine misidentification led
to consideration and analysis of 4 new problems that
informed design of a platform technology for delivering
a distributed medicine characterization: 1) problematic
interests associated with a focus on preventing counter-
feiting, 2) the complexity of the many ways that medi-
cines can deviate from expected identities, 3) the
challenge of choosing amongst a diversity of attribute
characterization technologies, and 4) the need for a flex-
ible and distributed data aggregation mechanism.
Problematic interests associated with a focus on
preventing counterfeiting
Inadequate commercial incentives for making medicines
affordable for the global majority [2,18] means that
most people in the world today must either rely on
charitable donations of medicines, with all the lack of
sustainability that such reliance entails [19], or must
seek out cheaper alternatives [20,21]. There is an unmet
need for safe and effective medicines that is not readily
satisfied by existing regulated sources. This unmet need
encourages under-regulated sources [20] where there
are many opportunities for misunderstanding and misre-
presenting what is being acquired [3].
In developing countries, drug procurement can
account for 40% of hospital expenditures [22]. This is a
valuable resource that can encourage agents with access
to the supply chain to divert supplies away from desig-
nated recipients or to infiltrate lower cost products and
substitute these for higher cost products. Indeed, in
many such countries large proportions (in some cases
more than 50%) of procured medicines are reported to
be “lost” during delivery [5,23]. What is lost is often
found elsewhere. However, the quality and provenance
of that diverted medicine is difficult to verify by end-
users because of the circuitous route taken by such
products to reach end-users.
Despite this lack of clarity as to provenance, semi-
stable supply chains exist, with many individuals being
aware of other agents upstream and downstream in
these chains. These informal supply chains link multiple
agents who simultaneously act as producers and consu-
mers of goods and services within a complex external
regulatory environment. Both licensed and informal
agents deal with complex and often ineffective domestic
regulatory regimes as well as with the diverse regulatory
environments of trading partners supplying the medi-
cines. These agents are constantly engaged in policy
arbitrage where they scan the overall regulatory environ-
ment and determine how to best exploit it; the more
chaotic this regulatory space, the greater the opportunity
for personal gain at the expense of public good. The
end-result is proliferation of supply chains where
attempts at top-down regulation and standardization
only create new policy arbitrage opportunities. Clarity
around what was being supplied all along these informal
supply chains enables self-policing behaviour to be rein-
forced while discouraging harmful acts such as deliber-
ately making and selling fake medicines.
Global policy initiatives to address the specific threats
of fake and substandard medicines exist [1,8], but devel-
oping a coordinated global response to this problem has
proved challenging at best. The World Health Organiza-
tion (WHO), for example, has enlisted the support of
international organizations, enforcement agencies,
national drug regulatory authorities, and NGOs to create
the International Medicinal Products Anti-Counterfeiting
Taskforce (IMPACT) through its 2006 Rome Declara-
tion. Compliance with IMPACT initiatives however relies
on voluntary international cooperation and national
legislation harmonization. Controversies over guideline
intentions have limited “IMPACT’si m p a c t ” [3]. Also a
recent economic analysis points out how from an indus-
try perspective it is more profitable to frame the problem
as one of abuse of intellectual property but from a public
health perspective there is a better cost-benefit return by
focusing instead on enabling local assessment of medi-
cine effectiveness [23].
Thus, an overemphasis on the policing aspects of
reducing exposure to counterfeit medicines is not only
challenged by the voluntary nature of harmonization
guidelines but also by a suspicions that the focus on
property rights is more geared towards protecting mar-
ket share of large pharmaceutical manufacturers rather
than simply protecting public health. Instead of focusing
regulations on meeting out punishment to purveyors of
fake pills, a public health perspective aimed at determin-
ing identity of the medicines and adjusting therapy
accordingly is suggested to prove more effective in the
long-term at minimizing harm to users of anti-malarials.
The complexity of the many ways that medicines can
deviate from expected identities
There are a variety of reasons that can lead to a pre-
sumed medicine being used as if it were a known pro-
duct when it is in fact it is something else (Figure 1). In
order to design a system that can help prevent such
mistakes, it is important to distinguish between several
subclasses of misidentified medicines. The term “fake” is
used here instead of counterfeit to avoid conflating pub-
lic health issues with intellectual property issues.
Although “substandard” has been used to refer to all
variants of a drug class that do not meet pharmaco-
poeial standards [9], it is more precise to restrict the
term for products that result from manufacturing proce-
dures that deviate from processes claimed by the manu-
facturers and distributors. The term “degraded” is used
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manufacturing due to product instability. With known
manufacturing standards and final product composition
the expected rate and form of degradation can be pre-
dicted for specific locations and storage conditions.
“Non-equivalent” refers to a more subtle class of
mistaken medicines. This is a catch-all class that includes
all medicines that are substituted for another better
known (and often branded) medicine but for a variety of
reasons are not truly functionally equivalent (e.g. do not
generate a biopharmaceutical response that closely
matches, within specified limits, that of the other medi-
cine being substituted for either deliberately or inadver-
tently). All of these different classes of misidentified
medicines are thus different from non-conforming medi-
cines which deviate from national formulary standards in
a known way. Non-conforming medicines can be legally
and ethically used if that known deviation is officially
acknowledged and worked around.
Each of these types of deviations from the specified
anti-malarial product identity have been detected in the
field [6]. Indeed non-equivalent and substandard medi-
cines seem more prevalent than outright fakes [8]. The
prevalence of non-equivalent anti-malarial will only
become more pronounced in the near future as the
result of a conjunction of trends: 1) increasingly diversi-
fied generic market, 2) increasingly complex distribution
chains, and 3) inevitable evolution of multiple forms of
resistance to widely used anti-malarials.
A key first step in characterizing the utility of a medi-
cine is identifying what it is. That knowledge in turns
enables retrieval of information concerning best practices
around use of that formulation. Recognition of the nature
of a medicine’s deviation from its presumed identity is
needed to effectively determine whether the medicine
can still be useful as a “non-conforming” medicine or
should be simply be disposed of so that it will not be
used inappropriately by others. Unfortunately non-
conforming medicines often are all that is available at
local distribution points and have often already been paid
so it is important to explore whether they might still be
useful. For example, the current system of routinely
specifying 2-3 year expiry dates is driven primarily by
marketing considerations. These products may still be
effective and useful even though they are represented as
degraded and therefore dangerous. Indeed, a recent
direct test of the stability of expired fixed dose combina-
tion artemether-lumefantrine anti-malarial tablets in
uncontrolled tropical conditions showed that chemical
composition was stable as long as 5 years past the stated
expiry date [22]. Under one system such expired pro-
ducts would have to be destroyed, under another a case
could be made for their use. On the other hand, many
compounds produced or procured as a specified formula-
tion with specific bio-pharmaceutical properties do
however, become poorer in quality over time because
they are improperly stored. Yet, their external appearance
and packaging may appear identical to the genuine
article. Sharing experiences about effectiveness of
accurately identified products with known provenance
could inform users of risks associated with use.
The challenge of choosing amongst a diversity of
attribute characterization technologies
Any point-of-use assessment system must at a minimum
allow end-users to verify the identity and source of the
product they are using. End-users need to be able to
directly confirm attributes characteristic of that product.
In principle, packaging-based verification tools may be
used [9,24] but these can still be subverted using mod-
ern print and packaging technology. Also, in many areas
of the world, significant redistribution of pills occurs
after the packaging has been removed [9,25]. More
recent material focused variants of this tracking
approach may be more difficult to subvert. For example,
Laser Surface Authentication (LSA) takes advantage of
the natural surface imperfections on product packaging
or the pill itself to create an intrinsic signature that can
Fake:  Medicines active pharmaceutical 
ingredient (API) content, formulation, source, 
as well as other components are deliberately 
misrepresented. 
Non-Equivalent:  Presumption of functional 
equivalence is incorrect. Will not cause equivalent
effect if used exactly like compound being substituted 
for.
Substandard:  New product does not meet 
specified standards. Safety and or efficacy are 
compromised because components not at 
specified levels or quality. 
Degraded: Known branded product distributed in 
ways unwarranted by brand owner. May include: 
expired, re-packaged, re-distributed , poorly stored. 
Packaging may be identical to original.
Figure 1 Ways that medication identity can be mistaken. The formulation and analytically determinable material attributes of the medicine-
a- hand can deviate from that specified by pharmacopoeial monographs describing the medicine whose use was intended in several ways.
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into a 2 D barcode on the packaging [26]. Low-cost por-
table scanners can then read that signal and verify
authenticity of the product through comparison with a
signature pattern registered with an international regula-
tor or through local comparison with a known reference
sample. Of course this approach can also be subverted
but at a greater cost to the perpetrators.
Photonic methods can be adapted to analyse single
tablets, for example by evaluating chemical taggants or
coatings features [27]. Light-based analytical tools for
verifying presence of active ingredients from spectral
analysis of product composition are also becoming avail-
able and increasingly portable [14,26,27]. Some variants
of Raman spectroscopy can be applied non-destructively
through packaging at different points in the supply
chain [14]. The chemically specific spectra generated
also can be converted into unique digital identity codes
for overt tagging. These approaches allow sequential
quantitative testing of deviations from registered refer-
ence standards at different stages of the supply chain
right up to the final dispensing step.
The need for a flexible and distributed data aggregation
mechanism
For such methods to be usefully incorporated into a
data-feed there is a need for a distributed form of data
aggregation and archiving. The Laboratory for Colla-
borative Diagnostics has developed a distributed means
of recording large amounts of sequentially related
image-based clinical laboratory diagnostic information.
Use of this BioTIFF methodology in charactering glob-
ally distributed diagnostic testing has been described
previously [13]. The same commodity cameras used in
recording and sharing results of microscope based char-
acterization of parasites can also be used to record and
share spectral and image based analysis of pill attributes.
Indexing these files and making the index network-
accessible enables Google-like searches of the resulting
database facilitating comparison of the attributes of the
medicine-at-hand to reference standards. This would
also allow medicine identity interrogators at all levels of
the supply chain to compare their results with other
recorded results and to form hypotheses about why the
medicine has the signature properties that it has or on
whether it is likely to be safe and effective if used as
planned. A repository of medicine attribute characteriza-
tion assessment results comprising of summaries of both
measured spectra and other measured physical para-
meters as well as local knowledge of the medicine’so r i -
gin could be built up by communicating local results to
a data aggregation service using standard internet proto-
cols or via telephony messaging modalities.
Results and Discussion
Real-time Medicine Characterization Data-Feeds
A system for tracking acquisition and intention to use
specific medicinal products at a point-of-use emerges as
a necessary element for ensuring safe and effective use
of medicines in regions where national and local govern-
ments have limited capacity to regulate the types of
medicines reaching end-users. Local assembly and
implementation of a distributed user focused medicine
characterization system seem feasible and possibly
necessary [4]. Figure 2 presents a design schema for
developing a network-based medicine characterization
surveillance system that produces real-time data feeds of
what is being encountered while serving a local need to
know what medicine is being used.
The data feed produced by the proposed medicine
attribute characterization system can simply be broad-
cast and tracked by interested parties or fed to network
based aggregation services. The successful use of
e-health kiosks and tele-centers in low-income settings
[5] and the increasing portability and commoditization
of the various forensic assessment methods like Raman
spectroscopy and telemicroscopy [13,14,26,27] means
that it is now possible, to deploy telemicroscopy-based
medicine attribute assessment technology almost any-
where. For example, a cost effective spectrometer has
been developed recently that is sensitive enough to dis-
criminate between different brands of Tylenol locally
available in Canada [28]. The open-source nature of
much of the software needed to establish such networks
means that there are no intellectual property barriers to
developing a medicine attribute tracking network [13].
The use of non-destructive imaging also results in the
use of fewer consumables. Costs-per-pill can be kept
low by increasing throughput and amortizing up-front
equipment costs over many tests. Most importantly
h o w e v e r ,t h ef l e x i b i l i t yo fb e i n ga b l et ou s ea n yf o r mo f
analytical device that can measure any useful identifying
attribute of the pill allows the system to be easily
adapted to local needs and contexts and supportable by
local resources.
This paper describes a conceptual design rather than a
fully operational system. Moreover, this design is such
that it could be implemented in a variety of ways. Figure 3
illustrates the different stakeholders and settings that
would have to be consulted and linked in order to set up
such a pill characterization system and associated real-
time data-feed. Recent attempts to objectively estimate
the level of exposure to suspect medicines have focused
on systematic random sampling methods [7-9]. In con-
trast, the design proposed is imagined first and foremost
as a service to the medicine end-user. It aims to be locally
controlled and sustained with the option of sharing
Pennefather et al. Malaria Journal 2010, 9:214
http://www.malariajournal.com/content/9/1/214
Page 5 of 8Figure 3 Diagrammatic representation of stakeholders and expected results that could be associated with development of a safePill-
net design.
User-Focused Assessment Systems. 
In contrast to supply-focused systems that work through policies ensuring 
good manufacturing regulations, standardization, rule enforcement, user-
focused systems aim to enable end-users to access information about pill 
attributes measured directly at the point-of-use  and compared to known 
attributes of reference standards for pattern matching. 
Non-Destructive Assessment Tools. 
Several new material assessment technologies like Laser Surface Analysis 
(LSA) and Raman spectroscopy have emerged recently that preserve the 
integrity of the product and packaging and can be applied sequentially at 
different points along the supply chain up to the point-of-use. Being digital 
and web enabled facilitates tracking
Network-Based Medicine Characterization Data Stream.
Data feed infrastructure accessible at any point in the supply chain.  Web-
based services can support accessioning, encryption, reinterpreting and 
curating of medicine attribute pattern data as well as managing access to that 
data. This allows medicine characterization transactions to be tracked at 
multiple levels for multiple purposes.
Misidentified Pill Problem. 
In  chaotic health systems found in the developing world it often is difficult 
to confirm the identity of  anti-malarial pills because of existence of 
multiple poorly regulated supply chains.  Knowledge of pill identity in the 
field is needed to guide  effective treatment of populations and individuals 
as is necessary fro infectious disease
Figure 2 Diagrammatic representation of key system design elements. Four elements are specified: 1) the misidentified pill problem, 2) a
user focussed assessment system, 3) non-destructive assessment tools, and 4) network-based medicine characterization data streams.
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In order to demonstrate the value of the design, it will be
necessary to develop a training set of medicines to
examine the capacity to deal with the diversity quality
variations likely to be encountered in the field. This
would entail requesting reference samples from
registered global manufacturers and distributors of, for
example, anti-malarial medications as well as sourcing
samples of those medicines in use from an opportunistic
global sample of diverse users. A multivariate principle
component analysis using many analytical chemistry
parameters combined with other determinants of medi-
cine physical and chemical signatures could then be used
to cluster commonly observed deviations from registered
standards [29]. Prototyping the design will require colla-
boration with a suitable user group associated with a well
defined health system.
Recently an advisory board convened by the manufac-
turer of Cortem® (a fixed combination of atimisinin and
lumefantrin) explored the problems and advantages of
using that drug to treat asymptomatic malaria carriers
[30]. It was pointed out that in many areas 30% of the
population can be classified in that category and repre-
sents a reservoir that must be dealt with if the burden
of disease is to be reduced. A system such as the one
described above that combines confirmation of the med-
icine identity and a diagnostic designation, in a way that
can be tracked and registered, could play an important
role in ensuring success of such an approach. The use
of such a system in post- marketing surveillance or in
demonstrating utility of off-label applications of existing
drugs by helping to register patient-observed-results
may provide the necessary economic justification for
private development of infrastructure enabling distribu-
ted identifying attribute characterization systems in high
income countries.
Conclusions
The major problem associated with exposure to medi-
cines of uncertain identity in general and dubious anti-
malarials in particular is that the degree to which their
identity and utility is misrepresented is not easily verifi-
able by end-users. This state of affairs can arise for
many reasons; the medicines can be fake, substandard,
degraded, or non-equivalent imitations (see Figure 1).
But the end-result is the same; the medicine is mista-
kenly believed to be a dosage form known to be safe
and effective provided it is used as specified in a recog-
nized pharmacopoeia. A combination of point-of-use
analytics and mass-serialization now makes it feasible to
evaluate drug provenance and identity (Figure 3) at each
step in the medicine supply chain from production to
final use. This approach allows end-users to verify the
nature of products in their possession before use and
adapt their procurement and use policies so as to
maximize benefits.
The proposed system being digital and web enabled
also allows for generation of real-time data feeds that
can provide health system designers, participants and
regulators with data about user experiences and expec-
tation in the field. This information is essential for
developing dynamic and adaptive medication monitoring
systems [4]. While real-time data feeds cannot answer
by themselves the question of whether the genuine arti-
cle is effective under local conditions, it does allow that
question to be asked without complications introduced
by uncertainty as to what medicine was actually used.
An opportunistic survey of the breadth of medicine
types to which end-users in developing countries are
being exposed to would help develop clearer hypotheses
about causes and consequences of a pandemic of expo-
sure to misiendentified medicines. Real-time medicine
attribute characterization data streams will ensure that:
1) that the true life cycle of medications will be known,
not guessed at; 2) the medication handed over at the
point of sale will actually be known as meeting certain
standards of therapeutic effectiveness or stability; and 3)
unusual environmental conditions that affect medicine
effectiveness can be monitored.
The system as described is designed simply to help
end-users and their suppliers keep track of what is
being used. In the future, as systems of this type become
more widely deployed, manufacturers will have the
opportunity to customize products for specific locations
and needs and build web-based information services to
replace printed package inserts explaining the purpose
of the specific formulation design. It also allows for
users to communicate their medication experience to
manufacturers, regulators, and other users if they so
chose. Also formulations may be specifically designed
with excipients and coatings that make them more easily
recognizable to digital analytical imaging devices as well
as the human eye. This form of digital protective pro-
duct packaging could support productive competition
around costs and effectiveness. Innovative manufacturers
will see the benefits of using this type of system to
document and communicate reasons for believing their
claims about why user should trust new lower cost
innovative product designed for specific markets.
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